ocugen_4C_LOGO (002).png
Ocugen to Present at 3rd Annual Dry AMD Therapeutics Summit
November 28, 2022 07:30 ET | Ocugen
MALVERN, Pa., Nov. 28, 2022 (GLOBE NEWSWIRE) -- Ocugen, Inc. (“Ocugen” or the “Company”) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene...
ocugen_4C_LOGO (002).png
Ocugen Provides Business Update & Third Quarter 2022 Financial Results
November 08, 2022 07:30 ET | Ocugen
Conference Call and Webcast Today at 8:30 a.m. ET Initiated dosing in the third and final cohort of U.S. Phase 1/2 OCU400 gene therapy clinical trialExpanded product pipeline with OCU500—Ocugen’s...
ocugen_4C_LOGO (002).png
Ocugen to Host Conference Call on Tuesday, November 8 at 8:30 A.M. ET to Discuss Business Updates and Third Quarter 2022 Financial Results
October 27, 2022 07:30 ET | Ocugen
MALVERN, Pa., Oct. 27, 2022 (GLOBE NEWSWIRE) -- Ocugen, Inc. (“Ocugen” or the “Company”) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene...
ocugen_4C_LOGO (002).png
Ocugen to Host R&D Day in New York City on Tuesday, November 1, 2022
October 19, 2022 07:30 ET | Ocugen
Highlighting Ocugen research and innovative technologies Featuring thought leaders in gene therapy and vaccines MALVERN, Pa., Oct. 19, 2022 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the...
ocugen_4C_LOGO (002).png
Ocugen Announces Completion of Dosing in OCU400 Phase 1/2 Cohort 2
October 12, 2022 17:37 ET | Ocugen
•  No safety concerns noted in ongoing clinical trial•  Study timeline remains on track MALVERN, Pa., Oct. 12, 2022 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a...
ocugen_4C_LOGO (002).png
Ocugen, Inc. to Present at Upcoming Vaccines, Cell & Gene Therapy Conferences
October 06, 2022 08:00 ET | Ocugen
MALVERN, Pa., Oct. 06, 2022 (GLOBE NEWSWIRE) -- Ocugen, Inc. (“Ocugen” or the “Company”) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene...
ocugen_4C_LOGO (002).png
Ocugen, Inc. to Present at Chardan’s 6th Annual Genetic Medicines Conference
September 29, 2022 07:30 ET | Ocugen
MALVERN, Pa., Sept. 29, 2022 (GLOBE NEWSWIRE) -- Ocugen, Inc. (“Ocugen” or the “Company”) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene...
ocugen_4C_LOGO (002).png
Ocugen Announces Agreement With Washington University in St. Louis for Commercialization of Intranasal COVID-19 Vaccine in U.S., Europe, and Japan
September 28, 2022 06:30 ET | Ocugen
Ocugen’s intranasal candidate is one of the world’s most advanced intranasal COVID-19 vaccinesIntranasal vaccine is designed to curb virus transmission and confer protective immunity MALVERN, Pa.,...
ocugen_4C_LOGO (002).png
Ocugen Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
September 16, 2022 17:07 ET | Ocugen
MALVERN, Pa., Sept. 16, 2022 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and...
ocugen_4C_LOGO (002).png
Ocugen Announces Publication of a Comprehensive Review of BBV152 in Frontiers in Immunology
September 14, 2022 06:30 ET | Ocugen
Data include the persistence of immune responses and protection against variants of concern, especially Delta and Omicron Ocugen has North American commercialization rights for BBV152, commercialized...